Literature DB >> 34216223

Why and how do we need comprehensive international clinical epidemiology of ARDS?

Gianni Tognoni1, Luigi Vivona2, Antonio Pesenti3,4.   

Abstract

Entities:  

Year:  2021        PMID: 34216223      PMCID: PMC8254436          DOI: 10.1007/s00134-021-06469-0

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
One of the most evident weaknesses of scientific and public health strategies in the management of the coronavirus disease 2019 (COVID-19) pandemic is certainly the scarcity of robust epidemiological data, not limited to the quali-quantitative descriptions of patient populations and their outcomes, specifically in the hardly comparable ICU settings of care [1-3], but aimed at what has become the core and the vocation of a clinically oriented epidemiological investigation. Clinical data collected and analysed with sound methodological criteria are the essential source of information, closely complementary to physio-pathological data for a better understanding of the causes of the outcomes of critical and still uncertain clinical conditions. The substantial absence of this type of epidemiology has suggested a broader question: whether and how far the failure documented in publications relating to the ICU phases of Covid-19 coincides with the state of the art also for the acute respiratory distress syndrome (ARDS), closely overlapping the severe pulmonary involvement seen in a small but dramatic fraction of the Covid-19-infected population. We felt that a targeted survey of the clinical epidemiological literature could provide an overview of the methodological strengths and weaknesses of recent research, and serve as an informed suggestion as to most practicable strategies. The main general results are summarised in Table 1 (the detailed bibliography examined is accessible on request), while the comments that follow underline the points which could be considered priority targets in the future.
Table 1

Outline and findings of the literature search: 2015–2019

Keywords: ARDS, Epidemiology, Mortality, ICU population
Quantitative findings: 1365 overall; 165 full-text articles assessed for eligibility; 41 studies included in qualitative synthesis (28 original articles, 13 systematic reviews and meta-analyses).
Evidences: The majority of studies cover retrospective or prospective analyses of monocentric or paucicentric series of cases included on the basis of widely heterogeneous criteria, analysed mainly descriptively, with no well-specified protocols to explore causal associations with contextual clinical care determinants of mainly in-hospital mortality.
Weaknesses and gaps: Absence of any stable and/or formal national, regional, international network (neither supported nor promoted by public actors or scientific societies) to describe, monitor, assess comparatively and periodically the characteristics and the determinants of the outcomes of the overall ARDS populations and of their main clinical sub-populations.
Outline and findings of the literature search: 2015–2019 Papers published to celebrate the 50th birthday of ARDS as a specific clinical entity and diagnosis show a clear consensus[4-7]: ARDS should become a model scenario to test the passage from the classical strictly descriptive estimates of its incidence and mortality (e.g., 10% of all ICU cases, 23% of all mechanically ventilated patients, 5.5 cases/ICU bed/year, 40% in-hospital mortality), to systematic monitoring of unmet clinical and technological needs in different care settings. The few long-term clinical studies reflect the practice in selected centers hardly representative of the broader spectrum of ICUs, and do not give a reliable epidemiological profile of ARDS based on hard clinical outcomes. Surprisingly, administrative databases, which have been the truly innovative protagonists of epidemiological information in all major areas of medicine, appear in only two contributions, both from the USA, with the classical indicators of population-based trends of incidence and prevalence of events and their short-term outcomes [8, 9]. Meta-analyses, which include just the selected trial populations, can only be used as retrospective epidemiological tools, suffering similar substantial limitations. A closer look at the most recent publications on ARDS (from 2015 onwards) does not really add much to our epidemiological knowledge, with the important exception of a formally planned project promoted by an international network of ICU clinicians [10] which makes important comparisons of the characteristics and the short-term outcomes of patients over a broad spectrum of countries and settings. A chapter that is confirmed as a marginal topic of research interest, despite important anticipations and suggestions [11], is the long-term outcome and burden of care of the ARDS survivors in the ICU [12]. A forward-looking interpretation of the above survey seems to confirm the structural and cultural reasons that make epidemiological research particularly difficult in intensive care and ARDS. The acute, intensive attention to complex clinical conditions, not easy to standardise, is certainly very demanding, relegating epidemiological research and the related data collection to a strictly occasional role. Because of its feared formal requirements of rigid pre-definition of the criteria required for reliable population analyses, an epidemiological approach seems an extra burden to be added to the already heavy tasks of clinical care, as well as of physiopathological and therapeutics-oriented research. The scarcity of large multicenter and multi-country epidemiological studies during the long period of the pandemic which has, however, seen the flexible and innovative implementation of population trials on treatments and vaccines seems to confirm the cultural distance between ICUs and comprehensive, real-time, not simply descriptive and retrospective, epidemiology. ARDS is part of this prospective, as model scenario, which should be reproduced for other critical conditions where planned complementarity of epidemiological and clinical information is expected to be highly effective in generating new knowledge and improving care. Sepsis [13] and septic shock [14] are a couple of similar priority areas for implementing the strategies summarised in Table 2 and commented below.
Table 2

Steps and strategies towards comprehensive ICU clinical epidemiology (CE)

Recognition of epidemiology as an integral component and resource in the ICU providing representative samples of the variability and comparability of the known, and the undefined, sub-populations about which innovative knowledge is required
Stable/permanent CE networks of ICUs representative of national, regional, international research interests
Scientific societies as the ‘natural’ promoters of networks/projects to be supported with public and private general and problem-targeted grants
Linkage and sharing of parallel or nested administrative, clinical, and basic research databases flexibly oriented toward predefined goals/clinical conditions
Definition of better targeted legal rules for the accessibility and sharing of individual patients’ data.
Steps and strategies towards comprehensive ICU clinical epidemiology (CE) Well planned utilization of the many administrative databases which are uniquely interesting components of the ‘big data’ world (where research investments and resources too are promised) is a priority. International cooperation in data sharing and comparative analyses must be a duty of scientific societies, in close collaboration with public authorities, to assure reliable, representative information to the general public on topics such as the ongoing pandemic. This meets their right to be briefed not just on how and where they die, but on what can be done to guarantee their health and life. Networking between clinical centres must be promoted to assure the independent nested integration of the administrative databases with the spectrum of physiopathological, clinical, diagnostic-therapeutic, and managerial information, with a view to comparing the many diversified determinants of different outcomes [15]. International networks need to be established to give visibility to the increasingly recognized, but easily forgotten or not adequately investigated, inter- and intra-countries inequalities and other differences. A further, complementary and much needed epidemiological instrument is the construction, starting from and linked to the above databases, as well as ex novo, of predefined cohorts of the many sub-populations that must be considered as parts of the overall population ‘diagnosed’ as Covid- or non-Covid-related ARDS. An accurate age-stratified approach, for instance, is indispensable, not simply as an obvious component of the often scantly informative multivariable approaches, but to explore in depth the clinical evolution of the disease with age. A specific focus on the characteristics and the burden of long-term care and mortality of Covid or no-Covid ICU survivors is an important objective, calling for close integration of administrative and clinical databases [16]. Our substantial ignorance on this important component of the post-acute phases of ARDS is one of the major gaps to be filled for an original contribution of epidemiology to the quality of care and innovative research not only for ARDS, but for the whole spectrum of clinical conditions and the ICU.
  16 in total

1.  A global perspective on the epidemiology of sepsis.

Authors:  Marc Moss; Gregory S Martin
Journal:  Intensive Care Med       Date:  2004-02-24       Impact factor: 17.440

2.  Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries.

Authors:  Giacomo Bellani; John G Laffey; Tài Pham; Eddy Fan; Laurent Brochard; Andres Esteban; Luciano Gattinoni; Frank van Haren; Anders Larsson; Daniel F McAuley; Marco Ranieri; Gordon Rubenfeld; B Taylor Thompson; Hermann Wrigge; Arthur S Slutsky; Antonio Pesenti
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

Review 3.  Lessons to learn from epidemiologic studies in ARDS.

Authors:  Bairbre A McNicholas; Grainne M Rooney; John G Laffey
Journal:  Curr Opin Crit Care       Date:  2018-02       Impact factor: 3.687

4.  Mortality Trends of Acute Respiratory Distress Syndrome in the United States from 1999 to 2013.

Authors:  Shea E Cochi; Jordan A Kempker; Srinadh Annangi; Michael R Kramer; Greg S Martin
Journal:  Ann Am Thorac Soc       Date:  2016-10

Review 5.  Fifty Years of Research in ARDS. Long-Term Follow-up after Acute Respiratory Distress Syndrome. Insights for Managing Medical Complexity after Critical Illness.

Authors:  Margaret S Herridge
Journal:  Am J Respir Crit Care Med       Date:  2017-12-01       Impact factor: 21.405

6.  Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.

Authors:  Giacomo Grasselli; Alberto Zangrillo; Alberto Zanella; Massimo Antonelli; Luca Cabrini; Antonio Castelli; Danilo Cereda; Antonio Coluccello; Giuseppe Foti; Roberto Fumagalli; Giorgio Iotti; Nicola Latronico; Luca Lorini; Stefano Merler; Giuseppe Natalini; Alessandra Piatti; Marco Vito Ranieri; Anna Mara Scandroglio; Enrico Storti; Maurizio Cecconi; Antonio Pesenti
Journal:  JAMA       Date:  2020-04-28       Impact factor: 56.272

7.  Short-Term Organ Dysfunction Is Associated With Long-Term (10-Yr) Mortality of Septic Shock.

Authors:  Adam Linder; Terry Lee; Jane Fisher; Joel Singer; John Boyd; Keith R Walley; James A Russell
Journal:  Crit Care Med       Date:  2016-08       Impact factor: 7.598

8.  National incidence rates for Acute Respiratory Distress Syndrome (ARDS) and ARDS cause-specific factors in the United States (2006-2014).

Authors:  Efe Eworuke; Jacqueline M Major; Lydia I Gilbert McClain
Journal:  J Crit Care       Date:  2018-07-10       Impact factor: 3.425

9.  Management and outcomes of acute respiratory distress syndrome patients with and without comorbid conditions.

Authors:  Elie Azoulay; Virginie Lemiale; Bruno Mourvillier; Maite Garrouste-Orgeas; Carole Schwebel; Stéphane Ruckly; Laurent Argaud; Yves Cohen; Bertrand Souweine; Laurent Papazian; Jean Reignier; Guillaume Marcotte; Shidasp Siami; Hatem Kallel; Michael Darmon; Jean-François Timsit
Journal:  Intensive Care Med       Date:  2018-06-07       Impact factor: 17.440

10.  COVID-19 in critical care: epidemiology of the first epidemic wave across England, Wales and Northern Ireland.

Authors:  Alvin Richards-Belle; Izabella Orzechowska; Doug W Gould; Karen Thomas; James C Doidge; Paul R Mouncey; Michael D Christian; Manu Shankar-Hari; David A Harrison; Kathryn M Rowan
Journal:  Intensive Care Med       Date:  2020-10-09       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.